| Identification | Back Directory | [Name]
DIF-3 | [CAS]
113411-17-9 | [Synonyms]
DIF-3 >=99% (HPLC), solid
1-Hexanone, 1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-
1-(3-Chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone, Differentiation-inducing factor 3 | [Molecular Formula]
C13H17ClO4 | [MDL Number]
MFCD05865230 | [MOL File]
113411-17-9.mol | [Molecular Weight]
272.72 |
| Chemical Properties | Back Directory | [Boiling point ]
416.9±45.0 °C(Predicted) | [density ]
1.240±0.06 g/cm3(Predicted) | [solubility ]
DMSO: 46 mg/mL, soluble | [form ]
solid | [pka]
5.92±0.45(Predicted) | [color ]
White to off-white | [InChI]
1S/C13H17ClO4/c1-3-4-5-6-8(15)11-9(16)7-10(18-2)12(14)13(11)17/h7,16-17H,3-6H2,1-2H3 | [InChIKey]
JWBMZIJMSBFBIY-UHFFFAOYSA-N | [SMILES]
CCCCCC(=O)c1c(O)cc(OC)c(Cl)c1O |
| Hazard Information | Back Directory | [Uses]
DIF-3 has been used: as a glycogen synthase kinase-3β (GSK-3β) activator to determine if GSK-3β is required for the anti-inflammatory actions of VU0360172 (VuPAM) in murine microglia, as a phosphorylation inhibitor for GSK-3β to examine the links between activation of protein kinase B (PKB)/GSK-3β/Fyn axis and nuclear factor erythroid 2–related factor 2 (NRF2) retention, as a GSK3β activator to study its effects on the cyclooxygenase 2 (COX2) expression levels in human primary chondrocytes in response to visfatin, as a GSK3β activator to study its effects on the intracellular mechanics along with F-actin and β-tubulin fiber networks in human primary chondrocytes | [Biological Activity]
Differentiation-inducing factor-3 (DIF-3) prevents the proliferation of intestinal cancer cells in vitro and in vivo. It may serve as a novel anti-cancer agent.''DIF-3 Inhibits cell cycle by inducing G0/G1 arrest. | [in vivo]
DIF-3 (150 mg/kg; p.o.; once a day for 5 days/week over 4 weeks) inhibits oxidative stress (0.2% KBrO3)-induced tumors in Mutyh-/- mice[1].
| Animal Model: | Mutyh-/- mice (KBrO3 dissolved in water at a concentration of 2 g/L was administered to 4-week-old mice for 12 weeks)[1] | | Dosage: | 150 mg/kg | | Administration: | Oral gavage (p.o.); once a day for 5 days/week over 4 weeks | | Result: | Markedly reduced the number of intestinal tumors, especially the number of large tumors with a diameter of >2.0 mm.
No differences in the appearance, activity, body weight, or blood cell counts.
The numbers of TCF7L2-and cyclin D1-positive nuclei in tumors were significantly decreased.
|
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|